Vendor Intelligence Report: Laicuinuo LCN

Published 3 Jul 2026. 17-page investigative report on who is behind Laicuinuo LCN: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 19 Finnrick lab tests, Laicuinuo LCN records 15 pass / 4 fail, for an overall pass rate of 79%. The useful read is product-specific, not vendor-wide: Tirzepatide is the stronger of the two measured peptides, while Retatrutide is the weaker and higher-concern choice. The lab record is also narrow, covering only two products, and ratings contract under stricter grading thresholds.

The corporate trail is thinner than the storefront language suggests. The investigation located a UK Xingruida wrapper now under active compulsory strike-off proceedings, while repeated Hong Kong and mainland China registry searches did not locate a matching Laicuinuo LCN / Xingruida registration. That does not prove the operation cannot ship; it does mean buyers are leaning heavily on lab history and batch-level verification rather than a stable, auditable corporate record.

The web footprint points to a centrally controlled storefront network rather than a single independent manufacturer site. hk-xrd.com, a Xingruida-branded sister domain, and a Laicuinuo mirror share copied boilerplate, distinctive text errors, CMS patterns, and infrastructure pivots. The report also found multiple direct-contact sales routes, Bitcoin acceptance, weak public review depth, and no located official-channel hierarchy or anti-counterfeit scheme.

Bottom line: Laicuinuo LCN is not a blanket avoid on the current Finnrick record, but it is a verification-required vendor with uneven product risk. Tirzepatide is the relatively better-tested option inside the measured catalog; Retatrutide is where buyers should demand cleaner lot evidence or consider a stronger product-specific source.

Inside the full report:

  • Per-product pass/fail rates, trajectory visuals, and methodology-divergence charts for both tested peptides
  • UK Companies House strike-off exhibits and officer-record analysis for the Xingruida wrapper
  • Registry-search findings across Hong Kong, mainland China, and the United Kingdom
  • Storefront-network analysis covering hk-xrd.com, hkxingruida.com, lecino.cn, shared CMS fingerprints, DNS, and IP pivots
  • Sales-channel, payment-recourse, and shipping-opacity review, including Bitcoin and WhatsApp-style contact routes
  • Outside-reporting, public-reputation, affiliate-scan, TikTok-lead, and dead-end findings

Risk assessment

  • Retatrutide quality-failure risk — high: Retatrutide has 8 Finnrick tests with 6 pass / 2 fail and a 76.95% rating; it is the weaker of the two measured Laicuinuo products.
  • Corporate and brand-authentication risk — high: No HK/CN registry match was located; the UK Xingruida wrapper is under active strike-off, and multiple mirror/sister domains operate without a located official-channel or anti-counterfeit scheme.
  • Tirzepatide quality-consistency risk — medium: Tirzepatide is the comparatively stronger measured product, but still has 11 Finnrick tests with 9 pass / 2 fail and a 79.88% rating.
  • Sales-channel and payment-recourse risk — medium: Multiple WhatsApp-style contact numbers and Bitcoin acceptance reduce transparency and recourse; outside reporting ties Xingruida to informal direct-message peptide selling.